Companies: Dexcom Inc.
Drugs: Stelo Glucose Biosensor System
FDA Clears First OTC CGM for Children: Dexcom Expands Stelo
200% citation coverage1 regulatory sources1 peer-reviewed sources
The FDA has cleared Dexcom Inc.’s Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children. The decision extends Stelo’s prior OTC clearance in adults and gives analysts a new regulatory catalyst to track in diabetes monitoring.
Intelligence Snapshot
Executive Summary
The FDA cleared Dexcom's Stelo as the first over-the-counter continuous glucose monitor for children age 2 and older who do not use insulin.
Key Insights
- This pediatric clearance extends Stelo's prior OTC approval in adults (March 2024).
- Stelo's labeled indication specifies individuals who do not use insulin.
-
The clearance applies the same integrated CGM (iCGM) device and technology to a younger…
The clearance applies the same integrated CGM (iCGM) device and technology to a younger population with the same non-insulin inclusion criterion.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | high |
| Investment | medium |
The FDA has cleared Dexcom Inc.'s Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children. The decision extends Stelo's prior OTC clearance in adults and gives analysts a new regulatory catalyst to track in diabetes monitoring.
Quick Answer
Key Questions
- What is the FDA approved over-the-counter continuous glucose monitor?
- What is the first over-the-counter CGM system?
- Who can use Stelo?
- What should regulatory teams track?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Stelo Glucose Biosensor System.
Unlock full calendar →Contents10 sections
FDA Clears First OTC CGM for Children: Dexcom Expands Stelo
FDA Expands Stelo's OTC Clearance to Children
The FDA has cleared Dexcom Inc.'s Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children, marking a regulatory expansion for the San Diego-based device maker. The clearance extends to individuals two years of age and older who do not use insulin.
This pediatric indication follows Dexcom's earlier milestone: the company secured OTC clearance for the Stelo system in adults 18 years and older in March 2024. The pediatric clearance now expands Stelo's labeled population to include children, provided they do not require insulin therapy.
IntelligenceRegulatory Impact
FDA decisions frame this story. Regulatory relevance is medium for diabetes, with Stelo Glucose Biosensor System most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key Takeaways
- The FDA cleared Dexcom's Stelo as the first over-the-counter continuous glucose monitor for children age 2 and older who do not use insulin.
- This pediatric clearance extends Stelo's prior OTC approval in adults (March 2024).
- Stelo's labeled indication specifies individuals who do not use insulin.
- The clearance applies the same integrated CGM (iCGM) device and technology to a younger population with the same non-insulin inclusion criterion.
IntelligenceCompetitive Intelligence
Competitive pressure is high. Dexcom Inc. reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.
Regulatory Rationale and Policy Context
The FDA's clearance decision reflects a stated focus on pediatric access and the clinical utility of real-time glucose data. According to the regulator's announcement, OTC CGMs can help pediatric patients and their caregivers build greater glycemic awareness, track patterns in response to meals and exercise, and make informed adjustments to support healthier long-term outcomes and quality of life.
The clearance is framed as an incremental regulatory extension rather than a novel platform approval. Stelo was already cleared as an integrated CGM (iCGM) for adults; the pediatric clearance applies the same device and technology to a younger population with the same non-insulin inclusion criterion.
IntelligenceMarket Signals
Commercial pull is medium and investment relevance medium for diabetes. Expect implications for pricing, access, and launch sequencing.
Timeline and Stelo's Regulatory Path
Dexcom's Stelo now carries two distinct OTC authorizations. The company first achieved OTC clearance for adults 18 and older in March 2024. The pediatric expansion followed, extending the labeled population to children two years of age and older.
The non-insulin restriction remains a defining boundary of Stelo's labeled use. Both the adult and pediatric indications specify patients who do not use insulin.
IntelligenceStrategic Takeaways
The FDA cleared Dexcom's Stelo as the first over-the-counter continuous glucose monitor for children age 2 and older who do not use insulin. This pediatric clearance extends Stelo's prior OTC approval in adults (March 2024). Stelo's labeled indication specifies individuals who do not use insulin.
What Regulators and Sponsors Are Studying
Ongoing clinical trial activity in glucose monitoring includes the Argus 2.0 Adoption Study (NCT07425236), which is not yet recruiting, and the Continuous Glucose Monitoring in Polycystic Ovarian Syndrome trial (NCT07392476), which is active but not recruiting.
IntelligenceEvidence Quality
Grounded in 1 regulatory source and 1 peer-reviewed source.
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT07425236 | Argus 2.0 Adoption Study | NOT_YET_RECRUITING | NA | KOS Inc. |
| NCT07392476 | Continuous Glucose Monitoring in Polycystic Ovarian Syndrome | ACTIVE_NOT_RECRUITING | — | The Cleveland Clinic |
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| University of Michigan | diabetes | 1 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | diabetes | 1 |
| University of Chile | diabetes | 1 |
| Istituto Nazionale di Ricovero e Cura per Anziani | diabetes | 1 |
| Amgen | diabetes | 1 |
| Bispebjerg Hospital | diabetes | 1 |
Timeline
- Not_Yet_Recruiting trial NCT07425236 (NA)
- Active_Not_Recruiting trial NCT07392476 (phase n/a)
Frequently Asked Questions
What is the FDA approved over-the-counter continuous glucose monitor?
The FDA cleared Dexcom Inc.'s Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children age 2 and older who do not use insulin. Stelo is also cleared OTC for adults 18 and older in the same non-insulin population.
What is the first over-the-counter CGM system?
Dexcom's Stelo Glucose Biosensor System was the first over-the-counter continuous glucose monitor cleared by the FDA, initially approved for adults 18 years and older in March 2024. The FDA has now extended that clearance to children, making Stelo the first OTC CGM for the pediatric population as well.
Who can use Stelo?
Stelo is indicated for individuals two years of age and older who do not use insulin.
What should regulatory teams track?
Regulatory and business development teams should monitor the labeled indications and any follow-on OTC glucose-monitoring clearances. Clinical trial activity in the CGM space, such as NCT07425236 and NCT07392476, may provide additional context on emerging use cases in glucose monitoring.
Continue Exploring
Jump into the entities behind this story.
Ask AI About diabetes
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow Stelo Glucose Biosensor System developments
FDA diabetes alerts and Stelo Glucose Biosensor System pipeline updates, every Monday.
- Sources analyzed
- 1
- Evidence strength
- 100/100
- Last verified
- Jun 13, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Critical source quality · grounded in cited primary and secondary sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
